We are live on ! Find out more
BMRN icon

BioMarin Pharmaceuticals
BMRN

418 hedge funds and large institutions have $14.8B invested in BioMarin Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 62 funds opening new positions, 160 increasing their positions, 133 reducing their positions, and 47 closing their positions.

New
Increased
Maintained
Reduced
Closed

32% more first-time investments, than exits

New positions opened: 62 | Existing positions closed: 47

20% more repeat investments, than reductions

Existing positions increased: 160 | Existing positions reduced: 133

6% more capital invested

Capital invested by funds: $14B → $14.8B (+$809M)

9% more call options, than puts

Call options by funds: $82.3M | Put options by funds: $75.7M

1% more funds holding

Funds holding: 414 → 418 (+4)

0.69% less ownership

Funds ownership: 98.49% → 97.8% (-0.69%)

18% less funds holding in top 10

Funds holding in top 10: 11 → 9 (-2)

Holders
418
Holders Change
+4
Holders Change %
+0.97%
% of All Funds
10.41%
Holding in Top 10
9
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-18.18%
% of All Funds
0.22%
New
62
Increased
160
Reduced
133
Closed
47
Calls
$82.3M
Puts
$75.7M
Net Calls
+$6.61M
Net Calls Change
+$11.7M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$971M
2
Primecap Management
Primecap Management
California
+$73.5M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$72.3M
4
Jennison Associates
Jennison Associates
New York
+$56.1M
5
ClearBridge Investments
ClearBridge Investments
New York
+$46M

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$91.7M
2
HM
HealthCor Management
New York
-$64.2M
3
Viking Global Investors
Viking Global Investors
Connecticut
-$46.5M
4
Victory Capital Management
Victory Capital Management
Texas
-$44.4M
5
Marshall Wace
Marshall Wace
United Kingdom
-$37M
Name Holding Trade Value Shares
Change 		Change in
Stake
OPPM
176
Opus Point Partners Management
New York
$2.89M +$119K +1,332 +4%
FLAM
177
First Light Asset Management
Minnesota
$2.77M -$14.9K -167 -0.5%
URS
178
Utah Retirement Systems
Utah
$2.74M – – –
NFA
179
Nationwide Fund Advisors
Ohio
$2.7M +$89K +1,000 +3%
TMAM
180
Tokio Marine Asset Management
Japan
$2.7M -$649K -7,296 -19%
AL
181
Airain Ltd
Guernsey
$2.68M +$2.71M +30,510 New
ANI
182
American National Insurance
Texas
$2.47M – – –
AC
183
Allstate Corporation
Illinois
$2.42M -$1.06M -11,900 -30%
FAT
184
First American Trust
California
$2.34M -$35.8K -402 -1%
Mitsubishi UFJ Asset Management
185
Mitsubishi UFJ Asset Management
Japan
$2.24M +$35.5K +399 +2%
GCIA
186
Gabelli & Co Investment Advisers
New York
$2.23M +$2.26M +25,450 New
CM
187
Crestline Management
Texas
$2.18M +$1.52M +17,106 +222%
BF
188
BOK Financial
Oklahoma
$2.14M -$1.01M -11,378 -32%
SG Americas Securities
189
SG Americas Securities
New York
$2.12M -$1.49M -16,765 -41%
GAMA
190
Graticule Asia Macro Advisors
New York
$2.11M +$2.14M +24,060 New
EU
191
Emory University
Georgia
$2.09M +$66.2K +744 +3%
OAM
192
Oppenheimer Asset Management
New York
$2.08M +$2.11M +23,721 New
Group One Trading
193
Group One Trading
Illinois
$2.07M -$6.91M -77,621 -77%
Retirement Systems of Alabama
194
Retirement Systems of Alabama
Alabama
$2M – – –
SAM
195
Shell Asset Management
Netherlands
$1.98M -$185K -2,085 -8%
AAM
196
Advisors Asset Management
Colorado
$1.97M -$592K -6,651 -23%
CG
197
Cutler Group
California
$1.96M +$1.05M +11,850 +113%
Janus Henderson Group
198
Janus Henderson Group
United Kingdom
$1.95M – – –
PIM
199
Partner Investment Management
California
$1.93M -$223K -2,510 -10%
CWM
200
CMH Wealth Management
New Hampshire
$1.93M -$26.9K -302 -1%
6 7
8
9 10

BMRN Hedge Fund Activity: Q1 2017 in Review

418 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q1 2017, worth a combined $14.8B — up 5.8% from $14B a quarter earlier.

Buyers outnumbered sellers: 62 funds opened new BMRN positions and 47 closed out — a net gain of 15 holders — while 160 added to existing stakes and 133 trimmed.

The largest buyer was BlackRock, adding an estimated $971M. The largest seller was JP Morgan Chase, cutting an estimated $91.7M.

  • 418 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q1 2017, up from 414 in Q4 2016.
  • Funds reported $14.8B of BioMarin Pharmaceuticals stock for Q1 2017, up 5.8% quarter-over-quarter.
  • 62 funds opened new BioMarin Pharmaceuticals positions in Q1 2017 and 47 closed out, a net change of +15 holders.
  • The largest BioMarin Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $971M added.
  • The largest BioMarin Pharmaceuticals seller in Q1 2017 was JP Morgan Chase, an estimated $91.7M sold.

Based on aggregated 13F filings for Q1 2017.